Please use this identifier to cite or link to this item: http://hdl.handle.net/1822/50079

TitleAlginate hydrogel improves anti-angiogenic bevacizumab activity in cancer therapy
Author(s)Ferreira, Natália N.
Ferreira, Leonardo M.B.
Miranda-Gonçalves, Vera
Reis, R. M.
Seraphim, Thiago V.
Borges, Júlio César
Baltazar, Fátima
Gremião, Maria Palmira D.
KeywordsProtein delivery system
Bevacizumab
Calcium alginate hydrogel
Tumor microenvironment
Supramolecular interactions
Issue date2017
PublisherElsevier
JournalEuropean Journal of Pharmaceutics and Biopharmaceutics
CitationFerreira, N. N., Ferreira, L. M., Miranda-Gonçalves, V., Reis, R. M., Seraphim, T. V., Borges, J. C., ... & Gremião, M. P. D. (2017). Alginate hydrogel improves anti-angiogenic bevacizumab activity in cancer therapy. European Journal of Pharmaceutics and Biopharmaceutics, 119, 271-282
Abstract(s)Anti-vascular endothelial growth factor (anti-VEGF) therapy applied to solid tumors is a promising strategy, yet, the challenge to deliver these agents at high drug concentrations together with the maintenance of therapeutic doses locally, at the tumor site, minimizes its benefits. To overcome these obstacles, we propose the development of a bevacizumab-loaded alginate hydrogel by electrostatic interactions to design a delivery system for controlled and anti-angiogenic therapy under tumor microenvironrnental conditions. The tridimensional hydrogel structure produced provides drug stability and a system able to be introduced as a flowable solution, stablishing a depot after local administration. Biological performance by the chick embryo chorioallantoic membrane (CAM) assay indicated a pH-independent improved anti-angiogenic activity (similar to 50%) compared to commercial available anti-VEGF drug. Moreover, there was a considerable regression in tumor size when treated with this system. Immunohistochemistry highlighted a reduced number and disorganization of microscopic blood vessels resulting from applied therapy. These results suggest that the developed hydrogel is a promising approach to create an innovative delivery system.that offers the possibility to treat different solid tumors by intratumoral administration.
TypeArticle
DescriptionAlginate hydrogel improves anti-angiogenic bevacizumab activity in cancer therapy
URIhttp://hdl.handle.net/1822/50079
DOI10.1016/j.ejpb.2017.06.028
ISSN0939-6411
Publisher versionhttp://www.sciencedirect.com/science/article/pii/S0939641116305628?via%3Dihub
Peer-Reviewedyes
AccessOpen access
Appears in Collections:ICVS - Artigos em Revistas Internacionais com Referee

Files in This Item:
File Description SizeFormat 
2017 ferreirann.pdf2,48 MBAdobe PDFView/Open

Partilhe no FacebookPartilhe no TwitterPartilhe no DeliciousPartilhe no LinkedInPartilhe no DiggAdicionar ao Google BookmarksPartilhe no MySpacePartilhe no Orkut
Exporte no formato BibTex mendeley Exporte no formato Endnote Adicione ao seu ORCID